Related Content
![Three doctors in white lab coats against a pink background Three doctors in white lab coats against a pink background](/sites/default/files/us/2023-05/Article%20-%20Press%20Release%20teaser%20cards.jpeg)
Pulmonary Fibrosis
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim, discusses the unmet needs of patients with IPF and other forms of progressive fibrosing ILDs and the FIBRONEER™ global clinical program
Read more
Related Press Release
![New Expanded Access Program for children and adolescents with fibrosing ILD New Expanded Access Program for children and adolescents with fibrosing ILD](/sites/default/files/us/2023-01/EAP.png)
October 17, 2022
Boehringer Ingelheim announces expanded access program
![New Phase III data in children presented at ERS 2022 New Phase III data in children presented at ERS 2022](/sites/default/files/us/2023-01/ERS2022.jpg)
September 25, 2022